Michael William Flores

Michael William Flores

Auto-generated profile, based on publicly available information

Michael William Flores

Health Equity Research Lab, Cambridge Health Alliance, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
CRCaryn R.R. Rodgers
Caryn R.R. Rodgers
MFMichael William Flores
Michael William Flores
OBObioesio Bassey
Obioesio Bassey
JAJenna M. Augenblick
Jenna M. Augenblick
BCBenjamin Cook
Benjamin Cook

1 November 2023 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
MFMichael William Flores
Michael William Flores
ASAmanda Sharp
Amanda Sharp
NCNicholas J. Carson
Nicholas J. Carson
BCBenjamin L. Cook
Benjamin L. Cook
Importance: The COVID-19 pandemic has contributed to poorer mental health and a greater need for treatment. Nationally representative estimates of major depressive disorder (MDD) and mental health treatment among US adolescents during the pandemic are needed.Objective: To estimate MDD prevalence among adolescents, evaluate mental health treatment use among adolescents with MDD, and assess differences by race and ethnicity.Design, Setting, and Participants: This cross-sectional analysis of the nationally representative 2021 National Survey on Drug Use and Health included noninstitutionalized US adolescents between the ages of 12 and 17 years (n = 10 743). Analytic weights were applied to all rates and model estimates to be nationally representative and account for sample design and survey nonresponse. Data were collected from January 14 to December 20, 2021, and analyzed from February 11 to April 3, 2023.Exposures: Self-reported race and ethnicity.Main Outcomes and Measures: Dichotomous outcomes of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition), MDD-specific mental health treatment, any type of mental health treatment, telehealth visits, and delays in mental health treatment.Results: The sample included 10 743 adolescents (51.1% male). Self-reported race and ethnicity included 5.1% Asian, 14.1% Black, 23.3% Latinx, 51.2% White, and 6.3% more than 1 race. Ages were evenly distributed: 34.0% aged 12 to 13 years; 33.3% aged 14 to 15 years; and 32.7% aged 16 to 17 years. Adolescents of more than 1 race or ethnicity had the highest MDD rate (26.5%). Compared with White adolescents, the lowest rates of any MDD treatment overall were found among Latinx adolescents (29.2% [95% CI, 22.2%-36.2%]) and those of more than 1 race or ethnicity (21.1% [95% CI, 11.6%-30.7%]). Similar results were found for treatment by any clinician (Latinx, 25.6% [95% CI, 18.8%-32.4%]; >1 race or ethnicity, 19.1% [95% CI, 9.7%-28.6%]), treatment by a mental health specialist (Latinx, 22.9% [95% CI, 16.9%-28.9%]; >1 race or ethnicity, 16.7% [95% CI, 7.1%-26.3%]), treatment by a nonspecialist clinician (Latinx, 7.3% [95% CI, 3.3%-11.3%]; >1 race or ethnicity, 4.8% [95% CI, 1.9%-7.7%]), and use of any psychotropic medication prescription (Latinx, 11.6% [95% CI, 7.3%-15.9%]; >1 race or ethnicity, 8.3% [95% CI, 2.8%-13.7]). Compared with White adolescents, Black adolescents had lower rates of MDD treatment by any clinician (31.7% [95% CI, 23.7%-39.8%]) and by nonspecialist clinicians (8.4% [95% CI, 3.8%-13.2%]) and experienced lower prescription rates for any psychotropic medication (12.6 [95% CI, 4.6%-20.6%]). Asian (16.0% [95% CI, 5.0%-27.2%]) and Latinx (17.8% [95% CI, 12.6%-23.0%]) adolescents had lower rates of virtual mental health treatment compared with White adolescents. Black (19.1% [95% CI, 14.1%-24.2%]) and Latinx (17.9% [95% CI, 15.0%-21.1%]) adolescents had lower rates of appointments transition to telehealth, while Black adolescents (14.1% [95% CI, 10.7%-17.4%]) experienced delays getting their prescriptions.Conclusions and Relevance: During the first full calendar year of the pandemic, approximately 1 in 5 adolescents had MDD, and less than half of adolescents who needed treatment had any mental health treatment. Adolescents in racial and ethnic minority groups, particularly Latinx, experienced the lowest treatment rates. Federal policy should target adolescents as a whole, and minority populations in particular, to ensure equitable treatment access. Efforts should consider the social, racial, ethnic, and cultural determinants of health.

1 December 2022 in Psychiatric Services
Verified
Journal Article
Closed access
KYKelly Guanhua Yang
Kelly Guanhua Yang
MFMichael William Flores
Michael William Flores
NCNicholas J. Carson
Nicholas J. Carson
BCBenjamin Cook
Benjamin Cook

15 February 2020 in Addiction
Verified
Journal Article
Closed access
PDF file
MFMichael William Flores
Michael William Flores
BCBenjamin Cook
Benjamin Cook
BMBrian Mullin
Brian Mullin
GHGabriel Halperin‐Goldstein
Gabriel Halperin‐Goldstein
ANAparna Nathan
Aparna Nathan
ZSZev Schuman‐Olivier
Zev Schuman‐Olivier

9 March 2023 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Open access
PDF file
MFMichael William Flores
Michael William Flores
ASAmanda Sharp
Amanda Sharp
FLFrederick Lu
Frederick Lu
BCBenjamin Lê Cook
Benjamin Lê Cook
Prescription opioids still account for a large proportion of overdose deaths and contribute to opioid use dependence (OUD). Studies earlier in the epidemic suggest clinicians were less likely to prescribe opioids to racial/ethnic minorities. As OUD-related deaths have increased disproportionately amongst minority populations, it is essential to understand racial/ethnic differences in opioid prescribing patterns to inform culturally sensitive mitigation efforts. The purpose of this study is to estimate racial/ethnic differences in opioid medication use among patients prescribed opioids. Using electronic health records and a retrospective cohort study design, we estimated multivariable hazard models and generalized linear models, assessing racial/ethnic differences in OUD diagnosis, number of opioid prescriptions, receiving only one opioid prescription, and receiving ≥18 opioid prescriptions. Study population (N=22,201) consisted of adult patients (≥18years), with ≥3 primary care visits (ensuring healthcare system linkage), ≥1 opioid prescription, who did not have an OUD diagnoses prior to the first opioid prescription during the 32-month study period. Relative to racial/ethnic minority patients, White patients, in both unadjusted and adjusted analyses, had a greater number of opioid prescriptions filled, a higher proportion received ≥18 opioid prescriptions, and a greater hazard of having an OUD diagnosis subsequent to receiving an opioid prescription (all groups p<0.001). Although opioid prescribing rates have declined nationally, our findings suggest White patients still experience a high volume of opioid prescriptions and greater risk of OUD diagnosis. Racial/ethnic minorities are less likely to receive follow-up pain medications, which may signal low care quality. Identifying provider bias in pain management of racial/ethnic minorities could inform interventions seeking balance between adequate pain treatment and risk of opioid misuse/abuse.

1 May 2020 in Health Affairs
Verified
Journal Article
Open access
BCBenjamin Cook
Benjamin Cook
MFMichael Flores
Michael Flores
SZSamuel H. Zuvekas
Samuel H. Zuvekas
JNJoseph P. Newhouse
Joseph P. Newhouse
JHJohn Hsu
John Hsu
VFVicki Fung
Vicki Fung
Before the implementation of cost-sharing parity in Medicare, beneficiaries faced higher cost sharing for mental health services than for other medical services. The Medicare Improvements for Patie...